1171MO PACIFIC-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

Autor:	Muriel Licour, Steven Kao, Nicolas Girard, W. Sawyer, F. Mornex, Andrea Riccardo Filippi, Fiona McDonald, Christos Chouaid, H.J.M. Smit, John K. Field, Daniel C. Christoph, V. Bray, Pilar Garrido, A. Allen, Solange Peters, M.C. Garassino, V.D. Haakensen, Jair Bar, R. Fietkau, A. Sibille
Rok vydání:	2021
Předmět:	Oncology medicine.medical_specialty Durvalumab business.industry Treatment duration Stage III NSCLC Hematology Interim analysis Internal medicine Medicine Progression-free survival business Chemoradiotherapy
Zdroj:	Annals of Oncology. 32:S939-S940
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2021.08.1775
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::4572328bad3813ae45b8cbe77ebfddbd https://doi.org/10.1016/j.annonc.2021.08.1775 Zobrazit plný text záznamu